ScreenPoint Medical Highlights Transpara Breast AI at RSNA 2025

ScreenPoint Medical is showcasing its Transpara Breast AI suite at the 111th Radiological Society of North America (RSNA) Annual Meeting in Chicago, announced in a press release. The suite includes AI tools for Detection, Density, and Temporal Comparison, designed to support radiologists in early cancer detection and workflow optimization.

In 2025, Transpara surpassed 11 million mammograms processed and is deployed across more than 30 countries. It has been selected by 40% of the top 20 hospitals in the United States, according to the U.S. News & World Report Honor Roll. The system is also part of two major randomized controlled trials—the MASAI study in Sweden and the $16 million PRISM trial in the U.S., which will begin in early 2026. The MASAI trial results showed a 29% increase in cancer detection and a 44% reduction in radiologist workload.

At RSNA, several studies highlight Transpara’s performance. Research from Johns Hopkins Medicine suggested that Transpara Detection could have identified 38% of interval breast cancers earlier. Another multi-site validation found improved specificity when prior exams were used. Additional studies compared four commercial AI algorithms for digital breast tomosynthesis, with Transpara Detection showing stronger results than competitors.

The company also presented findings on Transpara Risk, an image-based five-year breast cancer risk model currently approved for investigational use. A study presented at the conference demonstrated that combining risk prediction with detection improved precision care outcomes compared to existing systems such as RSNA CAD and Mirai.